Bayer Aktiengesellschaft (FRA:BAYA)
8.55
+0.15 (1.79%)
At close: Dec 5, 2025
Bayer Aktiengesellschaft Revenue
Bayer Aktiengesellschaft had revenue of 9.66B EUR in the quarter ending September 30, 2025, a decrease of -3.09%. This brings the company's revenue in the last twelve months to 45.87B, down -1.87% year-over-year. In the year 2024, Bayer Aktiengesellschaft had annual revenue of 46.61B, down -2.16%.
Revenue (ttm)
45.87B
Revenue Growth
-1.87%
P/S Ratio
0.71
Revenue / Employee
518.25K
Employees
91,864
Market Cap
32.72B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 46.61B | -1.03B | -2.16% |
| Dec 31, 2023 | 47.64B | -3.10B | -6.11% |
| Dec 31, 2022 | 50.74B | 6.66B | 15.10% |
| Dec 31, 2021 | 44.08B | 2.68B | 6.48% |
| Dec 31, 2020 | 41.40B | -2.15B | -4.93% |
| Dec 31, 2019 | Pro | Pro | Pro |
| Dec 31, 2018 | Pro | Pro | Pro |
| Dec 31, 2017 | Pro | Pro | Pro |
| Dec 31, 2016 | Pro | Pro | Pro |
| Dec 31, 2015 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| SAP SE | 36.49B |
| Siemens Aktiengesellschaft | 78.91B |
| Allianz SE | 105.02B |
| Deutsche Telekom AG | 121.02B |
| Siemens Energy AG | 39.08B |
| Rheinmetall AG | 11.00B |
| Münchener Rückversicherungs-Gesellschaft Aktiengesellschaft in München | 62.10B |
| Deutsche Bank Aktiengesellschaft | 29.86B |
Bayer Aktiengesellschaft News
- 1 day ago - EQS-News: Transforming Football: IBM and Bayer 04 Leverkusen Use AI for Superior Game Analysis - Wallstreet:Online
- 2 days ago - EQS-PVR: Bayer Aktiengesellschaft: Release according to Article 40, Section 1 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution - Wallstreet:Online
- 2 days ago - Evotec & Bayer Launch Phase 2 Trial for Alport Syndrome Treatment - Wallstreet:Online
- 2 days ago - EQS-News: Evotec-partner Bayer starts Phase 2 study for treatment of patients with Alport syndrome - Wallstreet:Online
- 2 days ago - Bayer Starts Phase IIa Study for Treatment of Patients With Alport Syndrome - Business Wire
- 3 days ago - RSNA25: Pediatric Study for Bayer's Investigational MRI Contrast Agent Gadoquatrane Meets Primary and Secondary Endpoints - Wallstreet:Online
- 3 days ago - RSNA25: Pediatric Study for Bayer's Investigational MRI Contrast Agent Gadoquatrane Meets Primary and Secondary Endpoints - Business Wire
- 3 days ago - Bayer (BAYRY) Achieves Milestone with Pediatric MRI Contrast Agent Study - GuruFocus